Table 3

Safety outcomes at 3 months grouped by onset to treatment times

Outcome	Onset to treatment times, min	Tenecteplase	Alteplase	OR (95%CI)	P value
Outcome	Onset to treatment times, min	No/total no (%)		OR (95%CI)	P value
Symptomatic intracranial haemorrhage within 36 hours
	0–90	0/43 (0)	0/41 (0)	--	--
	91–180	7/309 (2.3)	5/313 (1.6)	1.43 (0.45 to 4.55)	0.55
	181–270	8/356 (2.3)	8/350 (2.3)	0.98 (0.37 to 2.65)	0.97
Symptomatic intracranial haemorrhage within 90 days
	0–90	0/43 (0)	0/41 (0)	--	--
	91–180	7/309 (2.3)	7/313 (2.2)	1.01 (0.35 to 2.92)	0.98
	181–270	10/356 (2.8)	8/350 (2.3)	1.24 (0.48 to 3.17)	0.66
PH2 intracranial haemorrhage within 36 hours
	0–90	0/43 (0)	0/41 (0)	--	--
	91–180	5/309 (1.6)	0/313 (0)	--	--
	181–270	5/356 (1.4)	3/350 (0.9)	1.65 (0.39 to 6.95)	0.50
Any intracranial haemorrhage within 90 days
	0–90	1/43 (2.3)	1/41 (2.4)	0.95 (0.06 to 15.75)	0.97
	91–180	23/309 (7.4)	22/313 (7.0)	1.06 (0.58 to 1.95)	0.84
	181–270	20/356 (5.6)	27/350 (7.7)	0.71 (0.39 to 1.30)	0.27
Other significant haemorrhage events within 90 days
	0–90	0/43 (0)	0/41 (0)	--	--
	91–180	2/309 (0.7)	3/313 (1.0)	0.67 (0.11 to 4.06)	0.67
	181–270	3/356 (0.8)	2/350 (0.6)	1.48 (0.25 to 8.90)	0.67
Deaths
	0–90	3/43 (7.0)	1/41 (2.4)	3.00 (0.30 to 30.07)	0.35
	91–180	16/309 (5.2)	12/313 (3.8)	1.37 (0.64 to 2.95)	0.42
	181–270	26/356 (7.3)	22/350 (6.3)	1.18 (0.65 to 2.12)	0.59
Adverse events
	0–90	40/43 (93.0)	38/41 (92.7)	1.05 (0.20 to 5.54)	0.95
	91–180	275/309 (89.0)	271/313 (86.6)	1.25 (0.77 to 2.03)	0.36
	181–270	292/356 (82.0)	302/350 (86.3)	0.73 (0.48 to 1.09)	0.12
Serious adverse events
	0–90	10//43 (23.3)	5/41 (12.2)	2.18 (0.68 to 7.05)	0.19
	91–180	48/309 (15.5)	44/313 (14.1)	1.12 (0.72 to 1.75)	0.60
	181–270	57/356 (16.0)	57/350 (16.3)	0.98 (0.66 to 1.46)	0.92

PH2, parenchymal haematoma 2.